​Infectious Diseases and Microbiology - Hepatitis B ( Hepatitis B Virus)

​Infectious Diseases and Microbiology - Hepatitis B  ( Hepatitis B Virus) 
Hepatitis B
The hepatitis B virus (HBV) is the cause of hepatitis B. HIV can be passed on through intercourse, blood transfusions and other body fluids, injectable medication usage, and pregnancy.
HBV infection symptoms and clinical results can range from minor and self-limited to severe and persistent.
Subclinical HBV primary infections predominate. In 25% to 35% of cases, the infection results in acute hepatitis, which is characterized by fever, exhaustion, anorexia, nausea, and pain-associated hepatomegaly. Jaundice, dark urine, pale feces, and increased liver enzymes are signs of increased liver involvement. Serum contains HBV DNA, HBe antigen, and hepatitis B surface antigen (HBsAg), indicators of HBV infection. About 10% of HBV infections result in chronic hepatitis, which is characterized by the presence of HBsAg, HBV DNA, and HBeAg for at least six months. Individuals who have ongoing HBV are susceptible to hepatocellular cancer, liver failure, and liver cirrhosis.

Hepatocytes are infected by HBV, although direct cytopathology is not produced. The immunological onslaught by cytotoxic T cells is the cause of hepatocellular damage. People who are not able to eliminate the virus from their body develop into carriers of the virus, which leads to chronic hepatitis and cirrhosis. Cell-mediated immunity plays a key role in eradicating infection, and antibody against HBsAg offers protection.

Serologic assays and biochemical testing (liver enzymes, bilirubin) are used to diagnose HBV infection.
 Hepatitis B core antigen (HBcAg) IgM antibody is a sign of acute infection. Antibodies against HBsAg are linked to protection against HBV infection.

For acute hepatitis B, there is no particular treatment. Treatment options for chronic hepatitis B include entecavir, adefovir, lamivudine, and interferon-alpha. A recombinant HBsAg vaccine is used to achieve active immunization against HBV. After needlestick exposures and for neonates born to HBsAg(+) mothers, passive immunization with HBV immune globulin is administered. Steering clear of high-risk activity is a crucial preventive step.